Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DV8A1L
|
|||
| Drug Name |
CHDI-340246
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Huntington disease [ICD-11: 8A01.10; ICD-10: G10; ICD-9: 294.1, 333.4] | Preclinical | [1] | |
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Kynurenine 3-hydroxylase (KMO) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019 May;18(5):379-401. | |||
| REF 2 | The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease. Exp Neurol. 2016 Aug;282:99-118. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.